Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody

Metelimumab (CAT192) is a human IgG4 monoclonal antibody developed as a TGFβ1-specific antagonist. It was tested in clinical trials for the treatment of scleroderma but later terminated due to lack of efficacy. Subsequent characterization of CAT192 indicated that its TGFβ1 binding affinity was reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lord, Dana M., Bird, Julie J., Honey, Denise M., Best, Annie, Park, Anna, Wei, Ronnie R., Qiu, Huawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916551/
https://www.ncbi.nlm.nih.gov/pubmed/29333938
http://dx.doi.org/10.1080/19420862.2018.1426421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916551/
https://www.ncbi.nlm.nih.gov/pubmed/29333938
http://dx.doi.org/10.1080/19420862.2018.1426421

Ejemplares similares